Tonix Pharmaceuticals Holding Corp.(TNXP)

$12.55—

Chart

Tonix Pharmaceuticals Holding Corp.(TNXP)

NASDAQ

$12.55—

Chart Studio

TNXP(TNXP)

TNXP

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-2.50

Nov 9, 2026

Revenue Estimate

$14M

FY2030E EPS$0.14

Analyst Sentiment

Wall St. Consensus

Buy

7 analysts·Limited coverage

Score

6 Buy (86%)1 Hold (14%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

686%

Hold

114%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$27.00

+115.1%

Consensus

$27.00

+115.1%

Bull

$27.00

+115.1%

12-Month Target Range7 analysts

$27.00$27.00$27.00

Current $12.55Consensus

Current Price

$12.55

Upside to Consensus

$14.45

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+133.55%

EPS—

FY2028

Rev+76.44%

EPS—

FY2029

Rev+28.84%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$50M	$116M	$205M	$264M	$330M
Low	$36M	$60M	$127M	$182M	$227M
High	$79M	$177M	$306M	$364M	$454M
EBITDA Avg	$-10M	$-23M	$-41M	$-53M	$-66M
Low	$-16M	$-35M	$-61M	$-73M	$-91M
High	$-7M	$-12M	$-25M	$-36M	$-45M
EBIT Avg	$-10M	$-23M	$-41M	$-53M	$-66M
Low	$-16M	$-35M	$-61M	$-73M	$-91M
High	$-7M	$-12M	$-25M	$-36M	$-45M
Net Income Avg	$-85M	$-53M	$-21M	$-22M	$1M
Low	$-92M	$-71M	$-61M	$-33M	$737,172
High	$-79M	$-35M	$19M	$-13M	$2M
EPS Avg	$-9.99	$-6.49	$-2.99	$-2.57	$0.14
Low	$-10.76	$-8.32	$-7.14	$-3.83	$0.09
High	$-9.24	$-4.13	$2.25	$-1.54	$0.22
Analysts (Rev / EPS)	3 / 3	4 / 3	4 / 3	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$14M	$17M	$22M	$26M	$30M	$33M
Low	$10M	$10M	$16M	$19M	$22M	$24M
High	$25M	$32M	$34M	$40M	$47M	$52M
EBITDA Avg	$-3M	$-3M	$-4M	$-5M	$-6M	$-7M
Low	$-5M	$-6M	$-7M	$-8M	$-9M	$-10M
High	$-2M	$-2M	$-3M	$-4M	$-4M	$-5M
EBIT Avg	$-3M	$-3M	$-4M	$-5M	$-6M	$-7M
Low	$-5M	$-6M	$-7M	$-8M	$-9M	$-10M
High	$-2M	$-2M	$-3M	$-4M	$-4M	$-5M
Net Income Avg	$-41M	$-37M	$-34M	$-32M	$-30M	$-26M
Low	$-43M	$-43M	$-60M	$-56M	$-52M	$-45M
High	$-38M	$-28M	$-22M	$-21M	$-19M	$-17M
EPS Avg	$-2.48	$-2.20	$-2.07	$-1.92	$-1.78	$-1.57
Low	$-2.61	$-2.60	$-3.60	$-3.34	$-3.10	$-2.72
High	$-2.28	$-1.66	$-1.34	$-1.25	$-1.16	$-1.02
Analysts (Rev / EPS)	4 / 3	4 / 3	2 / 1	2 / 1	2 / 1	2 / 1

Earnings Surprises

Recent Analyst Actions

Aug 10, 2026Raymond James

Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James

Target:$27.00

+115.3%from $12.54

Jun 24, 2026Raymond James

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

Target:$26.00

+114.9%from $12.10

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance